Salesforce (NYSE:CRM) is set to report fiscal third-quarter results tomorrow after the close of trading, and Wedbush ...
Act now before it’s gone.😲 Analysts at Morgan Stanley gave a stern warning about President-Elect Trump's proposed tariffs, ...
The Stellantis 2024 roller coaster hit a new low with CEO Carlos Tavares’s abrupt resignation. Here are three areas a new CEO ...
Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...
The $7 billion RIA welcomes a seasoned professional to help scale the business and draw talent across its private-client and ...
Major technology stocks are positioned for a strong year-end rally as artificial intelligence initiatives accelerate and ...
The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for ...
Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback